Cooperative Agreement U01TS000354
Award Date 9/30/26
Completion Date 9/29/29
Dollars Obligated $298K
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Washington, USA
Similar Awards
- The Agency for Toxic Substances and Disease Registry awarded the Washington University Office of Sponsored Research Services $959,784 on September 30, 2025, under the State Capacity Building program (CFDA 93.240) to support the Multiple Air Pollutants in Amyotrophic Lateral Sclerosis (MAP-ALS) project. The award funds research examining the relationship between air pollutant exposure and ALS development and progression. The period of performance runs through September 29, 2028, with work...
- The Agency for Toxic Substances and Disease Registry awarded the Regents of the University of Michigan a $1,000,000 cooperative agreement on September 30, 2025, under the State Capacity Building program (CFDA 93.240) to conduct spectral flow cytometry research identifying new immune signatures that provide personalized amyotrophic lateral sclerosis (ALS) risk and progression biomarkers and therapeutic targets. Work is performed in Michigan with a period of performance through September 29, 2028....
- The Agency for Toxic Substances and Disease Registry (ATSDR) awarded Virginia Commonwealth University a Cooperative Agreement totaling $599,996 on September 30, 2025, to detect novel environmental risk factors in recently identified ALS clusters in Central Virginia under the State Capacity Building program (CFDA 93.240). The award funds investigation and characterization of amyotrophic lateral sclerosis clusters detected in Central Virginia, with work performed in Virginia. The period of...
- The Defense Health Agency awarded the Seattle Institute For Biomedical And Clinical Research $657,123 on September 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to investigate air pollution exposure during military deployment and liver cancer risk among United States veterans. The award funds a three-year project period ending August 31, 2029, with work performed in Seattle, Washington. The grant is structured as a Project Grant, a form of assistance that...
- The Defense Health Agency awarded Fred Hutchinson Cancer Center $1,092,877 on September 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to investigate air pollution exposure during military deployment and liver cancer risk among United States veterans. The three-year project runs through August 31, 2029, with performance based in Seattle, Washington. The award supports basic and applied biomedical research intended to transform health care for Service Members...
- Federal Grant Award Summary Wayfinder Biosciences Inc. received a $680,591 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to conduct research on a novel small molecule screening approach for direct and selective targeting of repeat expansion RNA in C9ORF72 Amyotrophic Lateral Sclerosis (ALS). The award, issued on June 15, 2025, with a completion date of December 14, 2026, funds hypothesis-driven biomedical research...
- The Department of Defense's Defense Health Agency awarded a $921,600 Project Grant to The General Hospital Corporation (Massachusetts General Hospital) to research the "Therapeutic Effects of Sulfide Catabolism and Novel Trisulfide Compounds for Amyotrophic Lateral Sclerosis." The grant, under the Military Medical Research and Development program (CFDA 12.420), supports foundational biomedical research aimed at developing novel treatments for amyotrophic lateral sclerosis (ALS)....
- The Defense Health Agency awarded the Seattle Institute for Biomedical and Clinical Research $1.1 million on June 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to investigate associations between military deployment and early-onset colorectal cancer mortality in veterans. The award, which represents a modification (P00001) transferring the grant from VA Connecticut Research and Education Foundation Inc., funds research activity through July 31, 2030, and is...
- The Defense Health Agency awarded a $929,948 Project Grant to The Washington University in St. Louis, Missouri to support the research project "TARGETING TDP-43 MITOCHONDRIAL MISLOCALIZATION IN ALS". This grant is funded through the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research aimed at improving the health and care of military service members, veterans, and their families. The research project will investigate mitochondrial...
- The Defense Health Agency awarded the University of Washington $769,887 through the Military Medical Research and Development program (CFDA 12.420) on May 15, 2026, to investigate preventing per- and polyfluoroalkyl substances (PFAS) neurotoxicity through folate pathway intervention. The award runs through May 14, 2029, with performance taking place in Seattle, Washington. The University of Washington Office of Sponsored Programs serves as the recipient, administering the grant through its Grant...